Prime Medicine Inc (NASDAQ:PRME) shares, rose in value on Friday, March 28, with the stock price down by -0.50% to the previous day’s close as strong demand from buyers drove the stock to $1.99.
Actively observing the price movement in the last trading, the stock closed the session at $2.00, falling within a range of $1.905 and $2.065. The value of beta (5-year monthly) was 1.853. Referring to stock’s 52-week performance, its high was $8.27, and the low was $1.65. On the whole, PRME has fluctuated by -17.77% over the past month.
With the market capitalization of Prime Medicine Inc currently standing at about $261.01 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Feb-27.
Wall Street analysts also predicted that the company’s y-o-y revenues would reach 3.43M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that PRME’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of PRME currently trading nearly -1.09% and -19.59% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 42.85, while the 7-day volatility ratio is showing 8.15% which for the 30-day chart, stands at 10.49%. Furthermore, Prime Medicine Inc (PRME)’s beta value is 1.91, and its average true range (ATR) is 0.21.
A comparison of Prime Medicine Inc (PRME) with its peers suggests the former has fared considerably weaker in the market. PRME showed an intraday change of -0.50% in last session, and over the past year, it shrunk by -70.12%%.
Data on historical trading for Prime Medicine Inc (NASDAQ:PRME) indicates that the trading volumes over the past 10 days have averaged 1.34 and over the past 3 months, they’ve averaged 1.14 million. According to company’s latest data on outstanding shares, there are 131.16 million shares outstanding.
Nearly 60.42% of Prime Medicine Inc’s shares belong to company insiders and institutional investors own 31.20% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 19.41 million shares as on 2025-03-14, resulting in a short ratio of 14.73. According to the data, the short interest in Prime Medicine Inc (PRME) stood at 2843.00 of shares outstanding as of 2025-03-14; the number of short shares registered in 2025-02-14 reached 18.06 million. The stock has fallen by -31.85% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the PRME stock heading into the next quarter.
